{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T23:00:28Z","timestamp":1784242828919,"version":"3.55.0"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Although the use of anticoagulants or antiplatelets is known to increase bleeding risk, there is limited evidence on whether they contribute to a higher incidence of intraocular hemorrhage in patients with age-related macular degeneration (AMD).<\/jats:p><\/jats:sec>Objective<\/jats:title>To examine the association between anticoagulant or antiplatelet use and clinically important intraocular hemorrhage requiring vitrectomy in patients with exudative AMD.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>In this nationwide, population-based, retrospective cohort study using the Korean Health Insurance Review and Assessment Service database, 149\u202f620 patients with exudative AMD older than 40 years were identified from May 1, 2014, to April 30, 2023.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Use of anticoagulants or antiplatelets.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The main study outcome was clinically important intraocular hemorrhage requiring vitrectomy. The analysis used a retrospective, longitudinal cohort study design using Cox proportional hazards regression analysis and Kaplan-Meier survival analyses (exposure vs nonexposure group) and a cross-sectional case-control study design using logistic regression analysis (hemorrhage vs no hemorrhage group). All analyses were adjusted for demographics and comorbidities.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 94\u202f449 patients (mean [SD] age, 71.8 [9.8] years; 55\u202f677 [59.0%] male) were included in the cohort study, and 8110 patients (mean [SD] age, 70.2 [9.6] years; 5090 [62.8%] male) were included in the case-control study. In the Cox proportional hazards regression analysis, anticoagulant or antiplatelet exposure was associated with a higher risk of intraocular hemorrhage requiring vitrectomy (adjusted hazard ratio, 1.15; 95% CI, 1.02-1.29). The incidence probability of intraocular hemorrhage requiring vitrectomy was higher in the exposure group than the nonexposure group. In the logistic analysis, the use of anticoagulants (adjusted odds ratio [aOR], 1.88; 95% CI, 1.45-2.44) or antiplatelets (aOR, 1.37; 95% CI, 1.19-1.57) was associated with intraocular hemorrhage requiring vitrectomy. The combined use of anticoagulants and antiplatelets showed the highest aOR (aOR, 2.28; 95% CI, 1.65-3.15). Higher medication adherence was also associated with a higher aOR of intraocular hemorrhage (aOR, 1.69; 95% CI, 1.45-1.97).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this nationwide cohort study of patients with exudative AMD, antithrombotic medications were associated with a higher risk of intraocular hemorrhage requiring vitrectomy. These results suggest the need for proactive communication and tailored monitoring strategies to help minimize such sight-threatening complications.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.31366","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T15:00:39Z","timestamp":1757602839000},"page":"e2531366","source":"Crossref","is-referenced-by-count":9,"title":["Antithrombotic Medications and Intraocular Hemorrhage Risk in Exudative Age-Related Macular Degeneration"],"prefix":"10.1001","volume":"8","author":[{"given":"Min Seok","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seonghee","family":"Nam","sequence":"additional","affiliation":[{"name":"Samil Pharm Co Ltd, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeongwoo","family":"Lee","sequence":"additional","affiliation":[{"name":"Samil Pharm Co Ltd, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Joon","family":"Woo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"issue":"6","key":"zoi250889r1","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1089\/jop.2012.0148","article-title":"Incidence and risk factors for macular hemorrhage following intravitreal ranibizumab injection for neovascular age-related macular degeneration.","volume":"29","author":"Moon","year":"2013","journal-title":"J Ocul Pharmacol Ther"},{"issue":"4","key":"zoi250889r2","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1097\/00006982-198300340-00017","article-title":"Vitreous hemorrhage in senile macular degeneration.","volume":"3","author":"Kreiger","year":"1983","journal-title":"Retina"},{"issue":"8","key":"zoi250889r3","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1097\/IAE.0000000000003098","article-title":"The incidence, characteristics, management, prognosis, and classification of breakthrough vitreous hemorrhage secondary to polypoidal choroidal vasculopathy.","volume":"41","author":"Zhao","year":"2021","journal-title":"Retina"},{"issue":"7","key":"zoi250889r4","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00417-010-1575-7","article-title":"Clinical characteristics of polypoidal choroidal vasculopathy in Chinese patients.","volume":"249","author":"Hou","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"zoi250889r5","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41598-019-57297-8","article-title":"Long-term clinical course after vitrectomy for breakthrough vitreous hemorrhage secondary to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.","volume":"10","author":"Kim","year":"2020","journal-title":"Sci Rep"},{"issue":"10","key":"zoi250889r6","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1097\/IAE.0b013e3181e2266d","article-title":"Epidemiology of the association between anticoagulants and intraocular hemorrhage in patients with neovascular age-related macular degeneration.","volume":"30","author":"Kiernan","year":"2010","journal-title":"Retina"},{"issue":"2","key":"zoi250889r7","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ajo.2009.08.033","article-title":"Subretinal hemorrhages associated with age-related macular degeneration in patients receiving anticoagulation or antiplatelet therapy.","volume":"149","author":"Kuhli-Hattenbach","year":"2010","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"zoi250889r8","doi-asserted-by":"publisher","first-page":"10560","DOI":"10.1038\/s41598-018-28938-1","article-title":"Risk factors for breakthrough vitreous hemorrhage after intravitreal anti-VEGF injection in age-related macular degeneration with submacular hemorrhage.","volume":"8","author":"Shin","year":"2018","journal-title":"Sci Rep"},{"issue":"20","key":"zoi250889r9","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"zoi250889r10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s40545-021-00385-w","article-title":"Estimating proportion of days covered (PDC) using real-world online medicine suppliers\u2019 datasets.","volume":"14","author":"Prieto-Merino","year":"2021","journal-title":"J Pharm Policy Pract"},{"issue":"4","key":"zoi250889r11","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3341\/kjo.2020.0014","article-title":"Prognostic factors and long-term surgical outcomes for exudative age-related macular degeneration with breakthrough vitreous hemorrhage.","volume":"34","author":"Kim","year":"2020","journal-title":"Korean J Ophthalmol"},{"issue":"8","key":"zoi250889r12","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/ceo.13198","article-title":"Long-term visual outcomes for treatment of submacular haemorrhage secondary to polypoidal choroidal vasculopathy.","volume":"46","author":"Kang","year":"2018","journal-title":"Clin Exp Ophthalmol"},{"key":"zoi250889r13","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/2963822","article-title":"Long-term outcome of eyes with vitrectomy for submacular and\/or vitreous hemorrhage in neovascular age-related macular degeneration.","volume":"2021","author":"Kawakami","year":"2021","journal-title":"J Ophthalmol"},{"issue":"5","key":"zoi250889r14","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1007\/s40123-023-00783-0","article-title":"Systemic risk factors for vitreous hemorrhage secondary to polypoidal choroidal vasculopathy.","volume":"12","author":"Liu","year":"2023","journal-title":"Ophthalmol Ther"},{"issue":"2","key":"zoi250889r15","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.jcjo.2012.01.005","article-title":"Hemorrhagic complications after intravitreal ranibizumab injection for polypoidal choroidal vasculopathy.","volume":"47","author":"Cho","year":"2012","journal-title":"Can J Ophthalmol"},{"issue":"10","key":"zoi250889r16","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1097\/IAE.0b013e31822528c8","article-title":"Vitreous hemorrhage complicating intravitreal tissue plasminogen activator and pneumatic displacement of submacular hemorrhage.","volume":"31","author":"Wu","year":"2011","journal-title":"Retina"},{"issue":"6","key":"zoi250889r17","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1007\/PL00007887","article-title":"Relationship between anticoagulant medication and massive intraocular hemorrhage in age-related macular degeneration.","volume":"238","author":"Tilanus","year":"2000","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"zoi250889r18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1538-7836.2007.02499.x","article-title":"Combined antiplatelet and anticoagulant therapy: clinical benefits and risks.","volume":"5","author":"Eikelboom","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"10","key":"zoi250889r19","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1161\/01.STR.0000141933.75462.c2","article-title":"Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients.","volume":"35","author":"Shireman","year":"2004","journal-title":"Stroke"},{"issue":"12","key":"zoi250889r20","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1001\/archinte.159.12.1322","article-title":"Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study.","volume":"159","author":"Gull\u00f8v","year":"1999","journal-title":"Arch Intern Med"},{"issue":"7","key":"zoi250889r21","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1111\/jth.13697","article-title":"Bleeding risk of antiplatelet drugs compared with oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-analysis.","volume":"15","author":"Melkonian","year":"2017","journal-title":"J Thromb Haemost"},{"issue":"7","key":"zoi250889r22","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0008-4182(00)80126-X","article-title":"Prevalence of ocular hemorrhage in patients receiving warfarin therapy.","volume":"35","author":"Superstein","year":"2000","journal-title":"Can J Ophthalmol"},{"issue":"3","key":"zoi250889r23","doi-asserted-by":"publisher","first-page":"461","DOI":"10.18240\/ijo.2017.03.21","article-title":"Vitreous haemorrhage: a population-based study of the incidence and risk factors in Taiwan.","volume":"10","author":"Wang","year":"2017","journal-title":"Int J Ophthalmol"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2838760\/kim_2025_oi_250889_1757001429.58563.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T15:00:40Z","timestamp":1757602840000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2838760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.31366","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,11]]}}}